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Abstract 
1,2-Diarylethylamines represent a class of molecules that have shown potential in pain, epilepsy, 
neurodegenerative disease and depression. Examples include lefetamine, remacemide, and 
lanicemine. Recently, several 1,2-diarylethylamines including the dissociatives diphenidine, 
methoxphenidine and ephenidine as well as the opioid MT-45, have appeared as ‘research 
chemicals’ or ‘legal highs’. Due to their rapid emergence little is known about their 
pharmacology. One of these, 1-[1-(2-fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane, 2-
F-DPPy), is available for purchase with purported dissociative effects meant to mimic 
phencyclidine (PCP) and ketamine. To better understand this emerging class, pharmacological 
investigations were undertaken for the first time on fluorolintane and its five aryl-fluorine-
substituted isomers. In vitro binding studies revealed high N-methyl-D-aspartate (NMDA) 
receptor affinity (Ki = 87.92 nM) and off-target affinities at several sites including 
norepinephrine (NET), serotonin (SERT) and dopamine (DAT) transporters, and sigma 
receptors. High affinities for DAT were observed, which were typically greater than NMDA 
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receptor affinities. Additional functional and behavioral experiments show fluorolintane 
inhibited NMDA receptor-induced field excitatory postsynaptic potentials in rat hippocampal 
slices and inhibited long-term potentiation induced by theta-burst stimulation in rat hippocampal 
slices with potencies consistent with its NMDA receptor antagonism. Finally fluorolintane 
significantly inhibited prepulse inhibition in rats, a measure of sensorimotor gating, with a 
median effective dose (ED50) of 13.3 mg/kg. These findings are consistent with anecdotal reports 
of dissociative effects of fluorolintane in humans. 
Keywords: NMDA receptor antagonist, legal high, fluorolintane, diphenidine, ketamine 
 
1. Introduction 
The past decade has witnessed an explosion in the number and availability of new psychoactive 
substances (NPS). These agents come from multiple pharmacological classes and are commonly 
produced to mimic the effects of classical psychoactive substances such as phytocannabinoids, 
psychostimulants, entactogens, dissociative anesthetics, sedative-hypnotics and hallucinogens 
while evading legislative restrictions. From the global perspective, the United Nations Office on 
Drugs and Crime (UNODC) reported the notification of 803 NPS in the period between 2009–
2017 (UNODC, 2018).  The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), responsible for collecting the information related to Europe, is currently monitoring 
over 670 substances that have emerged over the last 20 years (EMCDDA, 2018). One class of 
NPS are dissociative drugs, which emerged as an effort to supply uncontrolled alternatives to the 
classical psychoactive drugs, PCP and ketamine (Wallach and Brandt, 2018a, 2018b).  
1-[1-(4-methoxyphenyl)cyclohexyl]piperidine (4-MeO-PCP), is believed to be the first 
dissociative NPS, appearing around 2008. Other compounds soon followed with the earliest 
being structurally related to PCP (arylcyclohexylamines) and ketamine (β-
ketoarylcyclohexylamines). Continuing legislative restrictions pushed the market to explore new 
chemical spaces including the 1,2-diarylethylamines such as diphenidine (Fig 1.). Subsequently, 
a number of 1,2-diarylethylamines have appeared, including methoxphenidine (MXP) and 
ephenidine (DPE) (Morris and Wallach, 2014). Analytical and pharmacological investigations of 
some of these compounds have been conducted (Wallach et al. 2015, Wallach et al. 2016, 
McLaughlin et al. 2016, Geyer et al. 2016, Luethi et al. 2017, Lodge and Mercier. 2015, Kang et 
al. 2017, Katselou et al. 2018). These 1,2-diarylethylamines were found to be potent N-methyl-
D-aspartate (NMDA) receptor antagonists, with additional pharmacological effects including 
inhibition of monoamine transporters (Wallach et al. 2016, Luethi et al. 2017, Kang et al. 2017).  
The NMDA receptor is an ionotropic glutamate receptor believed to play a central role in the 
clinical and subjective effects of dissociative drugs in humans (Morris and Wallach. 2014, Lodge 
and Mercier. 2015, Ingram et al. 2018).  
The pharmacology of several NPS 1,2-diarylethylamines remain completely unexplored. One 
such example is 1-[1-(2-fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane, 2-F-DPPy). 
Anecdotal accounts of dissociative-type effects of fluorolintane in humans have been reported on 
Internet discussion forums (e.g., UKchemicalresearch.org, 2015).  To characterize the 
pharmacology of fluorolintane and related 1,2-diarylethylamines, experiments were conducted 
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with fluorolintane, its five possible aryl-fluorinated isomers and the non-fluorinated counterpart, 
DPPy. Pharmacological investigations included NMDA receptor binding studies using 
competitive displacement of [3H]MK-801 in rat forebrain, as well as binding studies at 40 
additional CNS sites, including receptors for serotonin, dopamine, norepinephrine, histamine, 
opioid and GABA, and transporters for serotonin, dopamine and norepinephrine. To investigate 
its functional activity at NMDA receptor, the effects of fluorolintane on NMDA receptor 
dependent field excitatory postsynaptic potentials (fEPSPs) and on the induction of long-term 
potentiation (LTP) via theta-burst stimulation (TBS) was determined in rat CA1 hippocampal 
slices. Finally, experiments evaluated the effect of fluorolintane on pre-pulse inhibition (PPI) in 
rats, an operational measure of sensorimotor gating that is disrupted by dissociative drugs such 
as PCP and ketamine (Geyer et al. 2001, Halberstadt et al. 2016).   
 
2. Materials & Methods 
2.1 Test drugs 
Fluorolintane, its five aryl-fluorine-positional isomers and DPPy were synthesized as 
hydrochloride salts as previously described (McLaughlin et al. 2016, Wallach et al. 2016). A full 
description of synthesis procedures and in-depth analytical characterizations are the subject of a 
different publication to be published later. In brief, compounds were synthesized using one-pot 
method previously described (McLaughlin et al. 2016, Wallach et al. 2016) and purified using 
flash column chromatography. The purified freebases were converted to the HCl salts and 
recrystallized multiple times. Compounds were characterized using high resolution mass 
spectrometry (HRMS) and were all within ±	5 ppm of theoretical molecular weights. Identify 
and/or purity was further determined using gas chromatography mass spectrometry (GC/MS), 
high performance liquid chromatography (HPLC), liquid chromatography mass spectrometry 
(LC/MS), gas chromatography infrared spectroscopy (GC/IR) and nuclear magnetic resonance 
experiments (1H, 13C, and 2-D hetero and homo-nuclear coupling experiments HMQC, HMBC 
and COSY as well as 19F in anhydrous d6-DMSO). Structures of isomers were confirmed using 
full NMR assignments. All compounds are 95% pure or greater (HPLC, GC/MS and NMR).  
2.2 NMDA receptor binding studies  
In vitro binding affinities (Ki) of target compounds were determined by utilizing competitive 
radioligand binding assays with (+)-[3-3H]-MK-801 ([3H]-MK-801, Perkin-Elmer, 15-30 
Ci/mmol), in accordance with established protocols (Reynolds and Sharma 1999, 2001) similar 
to previous investigations (Wallach et al. 2016, Colestock et al. 2017, Kang et al. 2017). Rat 
forebrain homogenate was used as the source of NMDA receptors (rat forebrain obtained from 
Pel-Freez Biologicals, Rogers, AR, USA) and prepared as described by Reynolds and Sharma 
(1999). Suspensions of 10 mM HEPES buffer (pH 7.4, 25°C) containing 100 µg/mL protein, 
1.36 nM (+)-[3H]-MK-801, 100 µM glutamate, 10 µM glycine and seven concentrations (10-4-10-
10 M) of unlabeled test drugs as HCl salts dissolved in HEPEs buffer (competitors) were 
incubated in the dark on a mechanical rocker at room temperature for 2 h. (+)-MK-801 hydrogen 
maleate (30 µM; MedChem Express, USA) was used to define nonspecific binding. The reaction 
was terminated by vacuum filtration using a 24-well cell harvester (Brandel, Gaithersburg, MD, 
USA) over presoaked (15 minutes) GF/B glass fiber filters (Brandel, Gaithersburg, MD, USA). 
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Filters were washed with room temperature HEPES buffer (15 mL). Tritium trapped on the filter 
was measured via liquid scintillation counting (Ultima Gold, Perkin Elmer), using a Beckman LS 
6500 multipurpose scintillation counter (BeckmanCoulter, USA) at 57% efficiency. IC50 values 
were obtained by utilizing Graphpad Prism 5.0 (GraphPad Software, La Jolla, CA, USA) using 
nonlinear regression with log of the concentrations plotted against percent specific binding. Ki 
values were calculated using the equation of Cheng and Prusoff (1973). The Kd for (+)-MK-801 
hydrogen maleate was determined to be 1.747 nM in previous studies. Protein concentrations 
were determined via the Bradford method using Coomassie protein assay reagent and rat 
albumin as standard (Fraction V, Sigma Aldrich, USA) (Bradford. 1976). Experiments were 
performed in duplicate and repeated three times. Finally (+)-MK-801 maleate (MedChem 
Express, USA) was also run (range 10-6-10-11, in duplicate, repeated three times) as a comparison 
control for this set of experiments. 
 
2.3 Non-NMDA receptor binding studies 
Competitive binding studies were conducted on fluorolintane and five isomers against 40 CNS 
receptors by the National Institute of Mental Health Psychoactive Drug Screening Program 
(NMH PDSP) using described methods (Besnard et al. 2012). Initially, target compounds were 
dissolved in dimethyl sulfoxide and screened for radioligand displacement against target 
receptors at 10,000 nM concentrations. Compounds showing >50% displacement of radioligand 
binding for a given protein target underwent secondary screenings at varying concentrations to 
determine Ki values. Compounds were run in triplicate and each plate contained a known ligand 
of the receptor as a positive control. Full experimental details are available in the NIMH PDSP 
assay protocol book (Roth. 2018). A table of radioligands and receptors is provided in the 
supplemental document.  
 
2.4 In vitro field excitatory postsynaptic potential (fEPSP) experiments 
Male Wistar rats (Crl:Wi; Charles River, UK) aged 10 weeks were killed by neck vertebral 
dislocation (Schedule 1 method) according to the United Kingdom (Scientific Procedures) Act of 
1986. Following rapid removal, brains were placed in artificial cerebrospinal fluid (aCSF) that 
consisted of 124 mM NaCl, 26 mM NaHCO3, 3 mM KCl, 1.4 mM NaH2PO4, 1 mM MgSO4, 2 
mM CaCl2, and 10 mM D-glucose and were continuously oxygenated with 95% O2 and 5% CO2.  
Parasagittal cuts were made at 400 µm intervals and hippocampal slices were removed and 
placed in a submerged recording chamber at 28–30°C. Recordings of synaptic activity were then 
made, analyzed and presented as described (Ceolin et al., 2012). Using a recording glass 
microelectrode positioned in the stratum radiatum of area CA1, stimuli (0.03 Hz) were delivered 
with a bipolar electrode placed on the Schaffer collateral to elicit field excitatory synaptic 
potentials (fEPSPs). The NMDA receptor-mediated component of the fEPSP (NMDA receptor-
fEPSP) was revealed by adding 10 µM NBQX, 50 µM picrotoxin and 1 µM CGP 55845 to the 
aCSF, which abolished AMPA and GABA receptor mediated transmission respectively. After 30 
min of stable control responses, one concentration of the individual test compounds was added to 
the perfusate for 4-6 h while recording NMDA receptor-fEPSP on-line using WinLTP (Anderson 
and Collingridge 2007).  
	 5	
For the LTP experiments slices were incubated for 2-3 h in fluorolintane (10 µM) before being 
transferred to the recording chamber. Once in the chamber the slices were continuously perfused 
with the drug until the end of the experiment. A theta burst stimulation (TBS) was delivered after 
30 min of stable baseline. The TBS consisted of a single train of 5 bursts (each of 5 stimuli at 
100Hz) separated by 200 ms (Park et al., 2016). Control experiments were performed identically 
but slices were never exposed to fluorolintane.   
 
 
 
2.5 In vivo pre-pulse inhibition (PPI) experiments 
2.5.1 Animals 
 
 Male Sprague–Dawley rats from Harlan Industries (Indianapolis, IN, USA; initial weight 
250–275 g) were housed in pairs under a 12 h reverse light/dark cycle (lights off at 0700 hours).  
A reversed light/dark cycle was used so that behavioral testing could be conducted during the 
animals’ awake phase.  Food and water were available ad libitum except during behavioral 
testing.  Animals were acclimatized for approximately 1 week after arrival prior to behavioral 
testing and maintained in Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) approved facilities that meet all federal and state guidelines.  Procedures were 
approved by the University of California San Diego institutional animal care and use committee.  
Principles of laboratory animal care were followed as well as specific laws of the USA. 
 
2.5.2 Apparatus 
 
 Eight startle chambers (SR-LAB system, San Diego Instruments, San Diego, CA, USA) 
were used to measure startle reactivity in rats (Mansbach et al. 1989, 1991).  The startle test 
chambers are sound-attenuated, lighted, and ventilated enclosures containing a clear 
nonrestrictive cylindrical Plexiglas stabilimeter, 8.2 cm in diameter.  A high-frequency 
loudspeaker mounted 24 cm above the Plexiglas cylinder produces all acoustic stimuli.  The peak 
and average amplitudes of the startle response are detected by a piezoelectric accelerometer.  At 
the onset of the startling stimulus, 100 x 1 ms readings were recorded, and the average amplitude 
used to determine the magnitude of the startle response (measured in arbitrary units).  A dynamic 
calibration system was used to ensure comparable stabilimeter sensitivity across test chambers. 
Sound levels were measured using the dB(A) scale. 
 
2.5.3 Acoustic startle test sessions 
 
 Acoustic startle test sessions consisted of startle trials (pulse-alone) and prepulse trials 
(prepulse + pulse).  The pulse-alone trial consisted of a 40 ms 120 dB pulse of broadband white 
noise.  Prepulse + pulse trials consisted of a 20 ms acoustic prepulse, an 80 ms delay, and then a 
40 ms 120 dB startle pulse (100 ms onset–onset).  There was an average of 15 s (range = 6–22 s) 
between trials.  During each inter-trial interval, the movements of the animals were recorded 
once to measure responding when no stimulus was present (data not shown).  Each startle session 
began with a 5 min acclimation period to a 65 dB broadband noise that was present continuously 
throughout the session.  The startle test session contained 12 pulse-alone trials and 36 
prepulse + pulse trials (12 prepulses each of 68, 71, and 77 dB [equivalent to 3, 6, and 12 dB 
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above background]) presented in a pseudo-randomized order.  Six pulse-alone trials were 
presented at the beginning and the end of the test session but were not used in the calculation of 
PPI values. 
 
2.5.4 Experimental Design 
 
 Fluorolintane was dissolved in water containing 5% Tween-80 and administered 
subcutaneously.  The injection volume was 1 mL/kg.  One week after arrival, animals were 
tested in a brief baseline startle/PPI session to create treatment groups matched for levels of 
startle and PPI.  On the testing day, rats were brought to the testing room and allowed to sit for 
60 min before receiving injections.  Animals (n=10/group, 40 total) were injected SC with 
vehicle or fluorolintane (3, 10, or 30 mg/kg) and then placed in the startle chambers 15 min later. 
 
2.5.5 Analysis 
 
 The amount of PPI was calculated as a percentage score for each prepulse + pulse trial 
type: %PPI = 100−{[(startle response for prepulse+pulse trial)/(startle response for pulse-alone 
trial)]×100}. Startle magnitude was calculated as the average response to all of the pulse-alone 
trials.  PPI data were analyzed with two-factor analysis of variance (ANOVA) with treatment as 
the between-subjects factor and trial type (prepulse intensity) as a repeated measure.  For 
experiments in which there was no significant interaction between drug and prepulse intensity, 
PPI data were collapsed across prepulse intensity and average PPI was used as the main 
dependent measure.  ED50 values were calculated using nonlinear regression (Prism 7.00, 
GraphPad Software, San Diego, CA).  Startle magnitude data were analyzed with one-factor 
ANOVA.  Post-hoc analyses were performed using Tukey’s studentized range method.  The 
alpha level was set at 0.05. 
 
3. Results 
 
3.1 NMDA receptor binding studies 
Binding affinities for the test compounds and related compounds at the NMDA receptors are 
presented in Table 1. [3H]MK-801 displacement curves for the seven 1,2-diphenylethylamines 
are included below in Fig 2. Of the seven compounds examined, five displayed moderate NMDA 
receptor binding affinities (DPPy, 3-F-DPPy, 4-F-DPPy, 2”-F-DPPy and 3”-F-DPPy), whereas 
fluorolintane (2-F-DPPy) displayed a high affinity and 4”-F-DPPy had extremely weak affinity. 
The rank order of potency of the series evaluated here for [3H]MK-801 displacement was found 
to be 2-F-DPPy > 3”-F-DPPy > DPPy > 2”-F-DPPy > 3-F-DPPy > 4-F-DPPy > 4”-F-DPPy.  
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3.3 Non-NMDA receptor interactions 
All six fluorinated isomers showed affinities at several non-NMDA receptor CNS binding sites 
(Fig 3.). These sites included monoamine transporters for dopamine (DAT), serotonin (SERT) 
and norepinephrine (NET) as well as sigma-1 and sigma-2 receptors. This observation is 
consistent with that seen previously for diphenidine, 2-MXP and related compounds (Wallach et 
al. 2016, Kang et al. 2017, Luethi et al. 2018). 3-F-DPPy had the highest DAT affinity of the 
series (12 nM) whereas fluorolintane had the lowest (327 nM). All compounds except 
fluorolintane had higher affinity at DAT than NMDA receptor. In the case of 3-F-DPPy, its 
affinity at DAT was ~52-fold higher than that for the NMDA receptor (632 nM). All compounds 
except fluorolintane and 4’’-F-DPPy showed affinities for NET below 10,000 nM. Similar to 
DAT, the affinities at NET were generally greater than affinities for the NMDA receptor with the 
exception of fluorolintane. Affinities at SERT were also detected though it was modest in most 
cases. Affinities for DAT were always greater than affinities at NET and SERT for a given 
compound. High-modest affinities for alpha2-adrenergic subtypes 2A, 2B and 2C were observed 
with most compounds. 4’’-F-DPPy had the highest affinities for these three subtypes reaching 
10-8-10-7 potency. Diphenidine and methoxphenidine were found to have modest affinities at 
various alpha2 subtypes previously (Wallach et al. 2016, Luethi et al. 2018) None of the 
compounds showed affinity for the µ-opioid receptor (MOR), consistent with previous work with 
diphenidine, methoxphenidine, ephenidine and related compounds. Several of the compounds 
did however exhibit low to moderate affinities at the k-opioid receptor (KOR), with the most 
potent being 2’’-F-DPPy (Ki = 642 nM). (Wallach et al. 2016, Kang et al. 2016). MT-45 and 
lefetamine are diarylethylamines which have been found to have opioid-like activity in various 
assays, including MOR and KOR affinities (Nakamura and Shimizu. 1976, Mannelli et al. 1989, 
Table 1. NMDA receptor binding affinities for fluorolintane, DPPy and positional fluorine isomers, and 
reference compounds using [3H]MK-801 in rat forebrains. Means ± SEM from at least three separate 
experiments run in duplicate. 
Compound Name IC50 (nM) Ki (nM) 
PCP (Wallach 2014) 
PCP (Colestock et al. 2017) 
91 ± 1.3 
34.7 ± 2.5 
57.9 ± 0.8 
22.1 ± 1.6 
Diphenidine (Wallach et al. 2016) 28.6 ± 3.5 18.2 ± 2.2 
Ketamine (Kang et al. 2017) 508.5 ± 30.1 323.9 ± 19.2 
(+)-MK-801  
(+)-MK-801 (Wallach et al. 2016) 
4.5 ± 0.20 
4.1 ± 1.6 
2.5 ± 0.11 
2.5 ± 1.0 
Memantine (Wallach et al. 2016) 594.2 ± 41.3 378.4 ± 26.3 
DPPy 498.7 ± 26.1 280.15 ± 14.67 
Fluorolintane (2-F-DPPy) 156.5 ± 8.9 87.92 ± 5.03 
3-F-DPPy 1,126.1 ± 119 632.64 ± 66.8 
4-F-DPPy 1,697 ± 146 953.37 ± 82.5 
2’’-F-DPPy 1,085.33 ± 31.3 609.74 ± 17.6 
3’’-F-DPPy 466.1 ± 16.7 261.84 ± 9.4 
4’’-F-DPPy 18,300 ± 300 10,282.77 ± 169 
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Baumann et al. 2018, De Montis et al. 1985). Finally, affinities at sigma-1 and sigma-2 receptors 
were detected with all six F-DPPy isomers, except 4-F-DPPy which lacked affinity at the sigma-
2 receptor (IC50 = >10,000 nM). Affinities at the sigma-1 receptor were higher than the sigma-2 
receptor for every compound. Modest affinities were seen previously with diphenidine and 
related compounds (Wallach et al. 2016).  
 
3.4 Effect on NMDA receptor-mediated field EPSPs.  
Fig 4. shows the effects of test drugs and reference compounds on fEPSPs recorded from 
CA1 synapses in hippocampal slices following Schaffer collateral stimulation. In Fig 4., 
appropriate selective compounds were used to block the AMPA and GABA receptor-mediated 
potentials and the stimulus strength was increased to provide a submaximal NMDA receptor-
fEPSP (Kang et al., 2017). The lower case “c” displays the maximal effect of the competitive 
NMDA receptor antagonist, D-AP5 (100 µM). The graph shows the average fEPSP amplitude of 
4-5 experiments expressed as a percentage of the baseline and after the perfusion of fluorolintane 
at concentrations of 1 µM (red), 3 µM, (blue) 10 µM (black).  
As shown in Fig 4., 1 µM of fluorolintane reduced the NMDA receptor-fEPSP by 19.4 ± 
3% after 90 minutes and 41.8 ± 4.3% after 240 minutes in a single experiment. The same pattern 
(Wilcoxon test, n=5, p<0.05, df=8) was observed in the pooled data of five different animals 
(mean ± SEM, n=5). To further probe this sensitivity of the NMDA receptor-fEPSP to 
fluorolintane, 3 µM and 10 µM fluorolintane were utilized in the same procedure. Effects on 
NMDA receptor-fEPSP were concentration dependent. The 3 µM concentration reduced the 
NMDA receptor-fEPSP significantly in a single experiment and within the pooled data by 37.1 ± 
4%, after 90 minutes and 60.4 ± 3% after 240 minutes of drug perfusion (mean ± SEM, n=5, 
Wilcoxon test, p<0.05, df=8)  10 µM of fluorolintane produced a strong reduction/inhibition of 
NMDA receptor-fEPSP of 66 ± 4% after 90 min perfusion and reaching a near peak of 85.9 ± 
1% after 240 min perfusion, as observed in a single experiment (Fig. 4) and in the pooled data 
(mean ± SEM, n=4, Wilcoxon test, p<0.05, df=8). Fig 4. displays the combination of the pooled 
data for each concentration suggesting an inhibitory concentration dependent effect of 
fluorolintane on NMDA receptor-fEPSPs. 
3.5 Effect on LTP induced by TBS.  
Previously we found that ephenidine blocks the induction of LTP induced by a standard Theta 
Burst Stimulation (TBS) protocol (Kang et al 2017), therefore, we next explored the ability of 
fluorolintane to block this form of synaptic plasticity at the CA1 Schaffer collateral pathway (Fig 
5.). Panel A and B show LTP elicited under control conditions and panel C and D show that LTP 
is blocked by fluorolintane (10 µM) in a fashion similar to that observed in the presence of D-
AP5 (Bliss and Collingridge 1993). Panels A and C represent single experiments whereas panels 
B and D show pooled data. 
 
3.6 In vivo Pre-pulse Inhibition Experiments 
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Similar to other NMDA receptor antagonists (Halberstadt et al. 2016, Wallach et al. 2016), 
fluorolintane significantly reduced PPI (F(3,36)=11.55, p<0.0001).  Although there was an 
interaction between treatment and prepulse intensity (F(6,72)=2.82, p=0.0159), the 30 mg/kg 
dose of fluorolintane reduced PPI at all three prepulse intensities (p<0.01, Tukey’s test).  
Therefore, Fig 6. shows the PPI data collapsed across the three prepulse intensities.  The dose of 
fluorolintane that produced a 50% reduction of average PPI (ED50) was 13.3 mg/kg (95% CI = 
8.8–20.0 mg/kg).  There was a significant main effect of prepulse intensity (F(2,72)=66.36, 
p<0.0001).  Fluorolintane did not alter the magnitude of the startle response to 120 dB acoustic 
stimuli (Main effect: F(3,36)=0.69, NS; Table 2).  
 
 
Table 2.  Effect of fluorolintane on startle magnitude 
Fluorolintane dose (mg/kg) N Startle Magnitude (mean ± SEM) 
0 10 186.18 ± 18.64 
3 10 235.10 ± 24.46 
10 10 161.53 ± 42.70 
30 10 195.28 ± 51.80 
 
 
 
4. Discussion 
It is unknown where 1,2-diarylethylamines bind to NMDA receptors, however given structural 
overlap with PCP (benzylamine moiety) and MK-801 (which can be viewed as a 
conformationally restrained 1,2-diarylethylamine), which bind to the PCP-binding site, it is 
probable that 1,2-diarylethylamines bind to the PCP-site labeled by [3H]MK-801. Additionally 
the kinetics of channel blockade by 1,2-diarylethylamines suggest an uncompetitive use-
dependent block rather than a competitive block as seen with AP5 (Wallach et al. 2016, Kang et 
al. 2017). Finally reasonable SAR overlap has been seen with respect to arylcyclohexylamines 
and 1,2-diarylethylamines with respect to the benzylamine moiety (Wallach et al. 2016, Kang et 
al. 2017).  
The compounds tested herein had lower NMDA receptor affinities than PCP, diphenidine and 
ephenidine. However fluorolintane and 3”-F-DPPy had higher NMDA receptor affinities than 
ketamine and memantine (Wallach et al. 2016, Kang et al. 2017, Colestock et al. 2017). The 
relatively high NMDA receptor affinity of fluorolintane is especially intriguing given the 
reported high affinity of 2-chlorodiphenidine (2-Cl-DPP), another ortho–halogen-substituted 1,2-
diarylethylamine (Wallach et al. 2016, Gray and Cheng. 1989). Thus 2-F or 2-Cl-substituions 
may increase affinity over the unsubstituted parent compounds. 
Consistency in the SAR for methoxy-substituted diphenidine analogs and their PCP counterparts 
for NMDA receptor affinity was reported (3-MeO- > 2-MeO- > 4-MeO-) (Wallach et al. 2016, 
Wallach. 2014, Gray and Cheng. 1989). Unfortunately little SAR information is available for F-
PCP analogs. Some information exists with the phenylcyclohexylamine (PCA) series and related 
arylcycloalkylamines (Thurkauf et al. 1990, Sun et al. 2014, Wallach. 2014). The structure 
activity relationship (SAR) of the fluorolintane series for NMDA receptor affinity (2-F-DPPy > 
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DPPy > 3-F-DPPy > 4-F-DPPy) did not match the PCA series (PCA > 3-F-PCA > 4-F-PCA > 2-
F-PCA, determined using [3H]TCP displacement in rat brain homogenates) (Thurkauf et al. 
1990). In the F-arylbicycloheptylamine series, the rank order [3H]MK-801 displacement, rat 
forebrain) was H- > 4-F ≥ 3-F > 2-F (Wallach. 2014). For arylcycloheptylamines F- substitution 
reduced affinity relative to the unsubstituted and a 3-F-substituent resulted in higher NMDA 
receptor affinity than 4-F (Sun et al. 2014), consistent with the PCA series (Thurkauf et al. 
1990). These results suggest some general SAR differences between the various benzylamine 
containing NMDA receptor antagonists, which may be helpful for selecting unique 
polypharmacology or pharmacokinetics. The NMDA receptor affinity for DPPy was reduced at 
least an order of magnitude relative to diphenidine. In general, PCP and PCPy and their aryl-
substituted counterparts were more or less comparable affinities (Wallach et al. 2014). Low 
affinity at the NMDA receptor with DPPy relative to diphenidine was reported previously (Gray 
and Cheng. 1989).  
Unfortunately, the SAR of F-arylcycloalkylamines for the NMDA receptor and monoamine 
transporters has not been systematically investigated although some information is known. 3-F-
PCP had modest NMDA receptor affinity (Ki = 1,150 nM), DAT (Ki = 891 nM) and NET (Ki = 
1,297 nM), but not SERT (IC50 >10,000 nM) (Wallach. 2014). Interestingly, the 
arylbicycloheptylamine, exo-1-[2-(3-fluorophenyl)bicyclo[2.2.1]heptan-2-yl]pyrrolidine (exo-3-
F-PBCHPy) had high affinity for DAT (Ki = 93 nM) and SERT (Ki = 32 nM) and the 2- and 4-F 
isomers had high SERT affinity but lower DAT affinity. These F-arylbicycloheptylamines all 
had low µM affinity for NET (Wallach. 2014). 
Consistent with the current study, high affinities for sigma receptors have been observed with 
many arylcycloalkylamines and 1,2-diarylethylamines, including diphenidine, 2-MXP and 
ephenidine (Wallach. 2014, Colestock et al. 2017, Wallach et al. 2016, Kang et al. 2017). The 
relevance of this remains unclear, but sigma-1 has been hypothesized as important in the actions 
of the NMDA receptor antagonist dextromethorphan (DXM) (Su et al. 2010, Nguyen et al. 
2014). 4-F-DPPy had low affinity at 5-HT2A (1,781 nM). PCP and ketamine were reported to 
have weak µM affinity and agonist activity at 5-HT2A (Kapur and Seeman. 2002). Likewise, a 
recent study reported similar weak µM affinity for diphenidine and 2-MXP at 5-HT2A (Luethi et 
al. 2018). The relevance of this is unknown.  
Consistent with related compounds (Wallach et al. 2015, Wallach et al. 2016, Kang et al. 2017), 
the slow inhibitory kinetics of fluorolintane in the EPSP experiments are more comparable to 
PCP, ketamine and memantine (uncompetitive NMDA receptor antagonists), as opposed to the 
rapid kinetics of D-AP5 (a competitive NMDA receptor antagonist). The slow kinetics of the 
antagonism suggest a requirement for channel opening to allow fluorolintane access to the 
binding site in the pore region of the NMDA receptor. From these findings along with in vitro 
binding data, it can be concluded that fluorolintane appears to be a modestly potent NMDA 
receptor antagonist, being more potent than ketamine and memantine in vitro but slightly less so 
than PCP and diphenidine (Wallach et al. 2016). 
Fluorolintane (10 µM) inhibited LTP formation induced by TBS in the Schaffer collateral CA1 
pathway of rat hippocampal slices with a potency comparable to its inhibition of NMDA receptor 
dependent fEPSPs. NMDA receptor antagonists are well known to prevent the induction of LTP 
following high frequency stimulation patterns including TBS (Collingridge et al., 1983, Stringer 
and Guyenet, 1983, Larson and Lynch 1988, Davis et al. 1992). For example it was previously 
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found that ephenidine blocked TBS-induction of LTP at 10 µM under comparable conditions to 
those used here (Kang et al. 2017). Such disruption in LTP induction with fluorolintane (10 µM) 
suggests that the drug potentially can cause cognitive disruption and amnesia (Bliss and 
Collingridge, 1993) and associated synaptic changes may be linked with the behavioural deficits 
observed in the PPI experiments. 
Both competitive and noncompetitive NMDA receptor antagonists produce dissociative effects, 
including hallucinations in humans (Domino 1992, Oye et al 1992, Herrling 1994; Steinberg et al 
1994, Grotta et al., 1995, Giroux and Scatton, 1996, Yenari et al., 1998). PPI is reduced by 
competitive and noncompetitive NMDA receptor antagonists in rodents (Mansbach and Geyer, 
1989, 1991, Bakshi et al., 1999, Depoortere et al., 1999, Halberstadt et al., 2016, Wallach et al., 
2016). The ability of NMDA receptor antagonists to induce hallucinations has been linked to 
reductions in subcortical gating, resulting in sensory flooding (Vollenweider and Geyer, 2001). 
Similarly, reductions in PPI may reflect an impairment of sensorimotor gating. Hence, the same 
information processing deficits contributing to the PPI disruption may be responsible for their 
dissociative and hallucinogenic effects of these compounds. The PPI data demonstrate that 
fluorolintane produces PCP- and ketamine-like behavioral effects in rodents. These results, 
however, do not address the mechanism-of-action for fluorolintane effects on PPI. Although 
NMDA receptor blockade is thought to underlie the PPI-disruptive effects produced by PCP and 
ketamine (Halberstadt et al. 2016), fluorolintane is not selective for NMDA receptors, meaning 
that other pharmacological mechanisms could potentially contribute to the effect on PPI. Follow-
up studies are planned to address this question.   
Fluorolintane inhibited PPI with modest potency, with an ED50 of 13.3 mg/kg. For comparison, 
diphenidine had an ED50 of 9.5 mg/kg (Wallach et al. 2016), whereas PCP and (S)-ketamine had 
ED50 values of 0.88 and 2.86 mg/kg respectively (Halberstadt et al. 2016). While NMDA 
receptor antagonist potency appears to correlate with PPI inhibition for some NMDA receptor 
antagonists including PCP and ketamine (Halberstadt et al. 2016), so far 1,2-diarylethylamines 
appear to be an exception. Interestingly, however, the reduced potency of 1,2-diarylethylamines 
in the PPI paradigm in rats is consistent with reports that these compounds also have reduced 
potency in humans compared to PCP (~ 10-fold consistent with the PPI potency difference) and 
related compounds with high NMDA receptor affinity. This observation indicates that PPI data 
in rats has utility as a predictive screen for dissociative effects and assessing potency of new 
dissociative drugs in humans. How various pharmacological effects (pharmacokinetic and 
pharmacodynamics) influence the potency remain to be established.   
The reason for the discrepancy between NMDAR affinity and PPI potency (and potency in 
humans with 1,2-diarylethylamines) may be due to pharmacokinetics (Wallach et al. 2016). For 
example, the tested 1,2-diarylethylamines may have: poor absorbance and distribution, high 
metabolic liability, or be substrates for efflux pumps. The high estimated logP of these 
compounds (diphenidine 5.05 cLogP ChemDraw Ultra) could limit absorbance and distribution 
however PCP has a comparable LogP value (PCP: 5.1) suggesting this is unlikely the full story 
(Kamenka and Geneste. 1981). Metabolism studies have been performed on several 1,2-
diarylethylamines (Wink et al. 2016, Elliot et al. 2015, Minakata et al. 2015) and show extensive 
metabolism, though biological elimination half-lives are unknown. Anecdotal reports from 
ingestion by humans, do not support large variability in route of administration (ruling out a first-
pass effect) and reports of several hour durations of dissociative effects are common (Wallach 
and Brandt. 2018b). These reports seem inconsistent with high metabolic liability. Efflux via the 
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human Pgp transporter was evaluated for ephenidine and the closely related N-isopropyl-1,2-
diphenylethylamine (DPiP). Ephenidine lacked substantial Pgp substrate activity at 
concentrations up to 500 µM, where DPiP had a Km of 4.6 µM (Meyer et al. 2013). Other 1,2-
diarylethylamines should be investigated at Pgp and other efflux transporters. Finally, 
unidentified pharmacodynamics differences such as NMDA receptor subtype selectivity or 
common off-target effects that reduce potency of the PPI response and dissociative effects in 
humans.  
 
5. Conclusion  
Fluorolintane, its five possible aryl-F-positional isomers were evaluated to better characterize 
their pharmacology. Compounds had a range of affinities for the NMDA receptor as well as 
several additional receptors including DAT and NET monoamine transporters and sigma-1 and 
sigma-2 receptors. Rank order of potency for NMDA receptor affinity was found to be 
fluorolintane (2-F-DPPy) > 3”-F-DPPy > DPPy > 2”-F-DPPy > 3-F-DPPy > 4-F-DPPy > 4”-F-
DPPy. The higher NMDA receptor affinity seen with 2-F-DPPy was unexpected based on 
current SAR knowledge with arylcycloalkylamines however is consistent with the high NMDA 
receptor affinity seen with the related 2-Cl-DPP. The high affinities observed for DAT was 
notable, with most compounds showing higher affinity at DAT than NMDA receptor. In fact 3-
F-DPPy had ~50-fold higher affinity at DAT than NMDA receptor. This trend suggests 
interesting polypharmacology to investigate with future experiments. Fluorolintane showed 
concentration dependent inhibition of NMDA receptor-fEPSP consistent with its action as an 
NMDA receptor channel blocker. Fluorolintane also prevented the induction of LTP by TBS in 
hippocampal slices with potency consistent with its NMDA receptor blockage. Finally, 
fluorolintane significantly reduced PPI with an ED50 of 13.3 mg/kg in rats. These results suggest 
fluorolintane acts as a dissociative drug in humans through antagonism of the NMDA receptor.   
 
Acknowledgements 
ZAB - supported by the Medical Research Council (Grant No. G0601812) and the European 
Research Council (Grant No. 341089). CM supported by the the Needham Cooper Trust (UK) 
ALH was supported by the National Institute on Drug Abuse (R01 DA041336), as well as by the 
Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Centre. We 
would also like to acknowledge the National Institute of Mental Health Psychoactive Drug 
Screening Program for receptor binding studies and finally the USciences USURF Program (NF) 
and USciences Spiers Fellowship (MD).  
 
6. References 
 
Anderson, W.W., Collingridge G.L., 2007. Capabilities of the WinLTP data acquisition program 
extending beyond basic LTP experimental functions. J. Neurosci. Methods. 162.1-2, 346-356. 
https://doi.org/10.1016/j.jneumeth.2006.12.018. 
 
	 13	
Baumann, M.H., et al., 2018. Pharmacological characterization of novel synthetic opioids (NSO) 
found in the recreational drug marketplace. Neuropharmacology. 134, 101-107. 
https://doi.org/10.1016/j.neuropharm.2017.08.016. 
 
Besnard, J., Besnard, J., Ruda, G.F., Setola, V., Abecassis, K., Rodriguiz, R.M., Huang, X.P., 
Norval, S., Sassano, M.F., Shin, A.I., Webster, L.A., Simeons, F.R., 2012. Automated design of 
ligands to polypharmacological profiles. Nature. 13, 215-220. 
https://doi.org/10.1038/nature11691. 
 
Bliss, T.V., Collingridge, G.L., 1993. A synaptic model of memory: long-term potentiation in the 
hippocampus. Nature. 361, 31–39. https://doi.org/10.1038/361031a0. 
 
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding. Anal Biochem. 72.1, 248–54. 
https://doi.org/10.1016/0003-2697(76)90527-3.  
 
Ceolin, L., Bortolotto, Z.A., Bannister, N., Collingridge, G.L., Lodge, D., Volianskis, A., 2012. 
A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic 
transmission in the hippocampus. Neurochem Int. 61.4, 517-522. 
https://doi.org/10.1016/j.neuint.2012.02.035. 
 
Cheng, Y., Prusoff, W.H., 1973. Relationship between the inhibition constant (Ki) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 
Biochem. Pharmacol. 22.23, 3099-3108. https://doi.org/10.1016/0006-2952(73)90196-2. 
 
Collingridge, G.L., Kehl, S.J., McLennan, H.T., 1983. Excitatory amino acids in synaptic 
transmission in the schaffer collateral-commissural pathway of the rat hippocampus. J. Physiol. 
334, 33-46.  
 
Davis, S., Butcher, S.P., Morris, R.G., 1992. The NMDA receptor antagonist D-2-amino-5-
phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral 
concentrations comparable to those that block LTP in vitro. J. Neurosci. 12 (1), 21-34. 
https://doi.org/10.1523/JNEUROSCI.12-01-00021.1992. 
 
De Montis, M.G., Devoto, P., Bucarelli, A., Tagliamonte, A., 1985. Opioid activity of 
lefetamine. Pharmacol Res Commun. 17.5, 471-478. 
 
Domino, EF., 1992. Chemical dissociation of human awareness: focus on non-competitive 
NMDA receptor antagonists. J. Psychopharmacol. 6, 418-424. 
Elliott, SP., Brandt, SD., Wallach, J., Morris, H., Kavanagh, PV., 2015. First reported fatalities 
associated with the ‘research chemical’ 2-methoxydiphenidine. J. Anal. Toxicol. 39, 287–293. 
https://doi.org/10.1093/jat/bkv006. 
 
EMCDDA, 2018. Fentanils and synthetic cannabinoids: driving greater complexity into the drug 
situationAn update from the EU Early Warning System June 2018. Lisbon, Portugal. 
	 14	
http://www.emcdda.europa.eu/system/files/publications/8870/2018-2489-td0118414enn.pdf 
(accessed 14 August 2018).  
 
Gray, N.M., Cheng, B.K., 1989. 1,2-diarylethylamines for treatment of neurotoxic injury. Patent 
EP 0346791 B1. https://patents.google.com/patent/EP0346791B1 (accessed 14 August 2018).  
 
Geyer, P.M., Daeid, N.N., Savage, K.A., Ramsay, D., Holland, C., Sutcliffe, O.B., 2016. Guilty 
by dissociation—development of gas chromatography–mass spectrometry (GC-MS) and other 
rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances 
(NPSs). Anal. Bioanal. Chem. 408.29, 8467-8481. https://doi.org/10.1007/s00216-016-9969-y. 
 
Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R., 2001. Pharmacological studies 
of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in 
review. Psychopharmacology. 156.2-3, 117-154. https://doi.org/10.1007/s002130100811. 
 
Grotta, J., Clark, W., Coull, B., Pettigrew, L.C., Mackay, B., Goldstein, L.B., Meissner, I., 
Murphy, D., LaRue, L., 1995. Safety and tolerability of the glutamate antagonist CGS 19755 
(selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke. 
26.4, 602-605. 
 
Halberstadt, A.L., Slepak, N., Hyun, J., Buell, M.R., Powell, S.B., 2016. The novel ketamine 
analog methoxetamine produces dissociative-like behavioral effects in rodents. 
Psychopharmacology (Berl). 233.7, 1215-1225. https://doi.org/10.1007/s00213-016-4203-3. 
 
Herrling, P., 1994. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from 
animal models and first results in humans. Neuropsychopharm. 10, 591S. 
 
Ingram, R., Kang, H., Lightman, S., Jane, D.E., Bortolotto, Z.A., Collingridge, G.L., Lodge, D., 
Volianskis, A., 2018. Some distorted thoughts about ketamine as a psychedelic and a novel 
hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology. In 
Press. https://doi.org/10.1016/j.neuropharm.2018.06.008 
 
Kamenka, JM., Geneste, P., 1981. Synthesis, conformation, and physical properties of 
phencyclidine and its derivatives. In: Domino EF (ed) PCP (phencyclidine): historical and 
current perspectives. NPP Books, Ann Arbor, pp 47–82. 
 
Kang, H., Park, P., Bortolotto, Z.A., Brandt, S.D., Colestock, T., Wallach, J., Collingridge, G.L., 
Lodge, D., 2017. Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor 
antagonist properties. Neuropharmacology. 112(Pt A), 144-149. 
https://doi.org/10.1016/j.neuropharm.2016.08.004. 
 
Kapur, S., Seeman, P., 2002. NMDA receptor antagonists ketamine and PCP have direct effects 
on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. 
Mol. Psychiatry. 7.8, 837–844. https://doi.org/10.1038/sj.mp.4001093. 
 
	 15	
Larson, J., Lynch, G., 1988.  Role of N-methyl-D-aspartate receptors in the induction of synaptic 
potentiation by burst stimulation patterned after the hippocampal theta-rhythm. Brain Res. 441, 
111–118. https://doi.org/10.1016/0006-8993(88)91388-1. 
 
Lodge, D., Mercier, MS., 2015. Ketamine and phencyclidine: the good, the bad and the 
unexpected. Br. J. Pharmacol. 172, 4254–4276. https://doi.org/10.1111/bph.13222.  
 
Luethi, D., Hoener, M.C., Liechti, M.E., 2018. Effects of the new psychoactive substances 
diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur. J. Pharmacol. 
819, 242-247. https://doi.org/10.1016/j.ejphar.2017.12.012. 
 
Mannelli, P., Janiri, L., De Marinis, M. and Tempesta, E., 1989. Lefetamine: new abuse of an old 
drug—clinical evaluation of opioid activity. Drug Alcohol Depend. 24.2, 95-101. 
https://doi.org/10.1016/0376-8716(89)90071-9. 
 
Mansbach R.S., Geyer M.A., 1991. Parametric determinants in pre-stimulus modification of 
acoustic startle: interaction with ketamine. Psychopharmacology (Berl). 105.2, 162–168. 
https://doi.org/10.1007/BF02244303. 
  
Mansbach R.S., Geyer M.A., 1989. Effects of phencyclidine and phencyclidine biologs on 
sensorimotor gating in the rat. Neuropsychopharmacology. 2.4, 299–308. 
https://doi.org/10.1016/0893-133X(89)90035-3. 
 
McLaughlin, G., Morris, N., Kavanagh, P.V., Power, J.D., O'Brien, J., Talbot, B., Elliott, S.P., 
Wallach, J., Hoang, K., Morris, H. and Brandt, S.D., 2016. Test purchase, synthesis, and 
characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta and para-
substituted isomers. Drug Test. Anal. 8.1, 98-109. https://doi.org/10.1002/dta.1800. 
 
Meyer, MR., Orschiedt, T., Maurer HH., 2013 Michaelis-Menten kinetic analysis of drugs of 
abuse to estimate their affinity to human P-glycoprotein. Toxicol. Lett. 217, 137–142. 
https://doi.org/10.1016/j.toxlet.2012.12.012. 
 
Minakata, K., Yamagishi, I., Nozawa, H., Hasegawa, K., Wurita, A., Gonmori, K., Suzuki, M., 
Watanabe, K., Suzuki O., 2015. Diphenidine and its metabolites in blood and urine analyzed by 
MALDI-QTOF mass spectrometry. Forensic Toxicol. 33, 402–408. 
https://doi.org/10.1007/s11419-015-0273-x. 
 
Morris, H., Wallach, J., 2014. From PCP to MXE: a comprehensive review of the non medical 
use of dissociative drugs. Drug Test Anal. 6.7-8, 614-632. https://doi.org/10.1002/dta.1620.  
 
Nakamura, H., Shimizu, M., 1976. Comparative study of 1-cyclohexyl-4-(1, 2-diphenylethyl)-
piperazine and its enantiomorphs on analgesic and other pharmacological activities in 
experimental animals. Arch Int Pharmacodyn Ther. 221.1, 105-121.  
 
	 16	
Nguyen, L., Robson, M.J., Healy, J.R., Scandinaro, A.L., Matsumoto, R.R., 2014. Involvement 
of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PloS one. 9.2, 
e89985. https://doi.org/10.1371/journal.pone.0089985. 
 
Oye I, Paulsen O, Maurset A. 1992. Effects of ketamine on sensory perception: evidence for a 
role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260, 1209-1213. 
Park, P., Sanderson, T.M., Amici, M., Choi, S.L., Bortolotto, Z.A., Zhuo, M., Kaang, B.K., 
Collingridge, G.L., 2016. Calcium-permeable AMPA receptors mediate the induction of the 
protein kinase A-dependent component of long-term potentiation in the hippocampus. J. 
Neurosci. 36.2, 622-631. https://doi.org/10.1523/jneurosci.3625-15.2016. 
 
Reynolds I.J., 2001. [3H](+) MK801 Radioligand Binding Assay at the N-Methyl-D-Aspartate 
Receptor. Curr Protoc Pharmacol. 11.1, Chapter 1. 
https://doi.org/10.1002/0471141755.ph0120s11. 
 
Reynolds, I.J., Sharma, T.A., 1999. The use of ligand binding in assays of NMDA receptor 
function. Methods Mol Biol. 128, 93–102. https://doi.org/10.1385/1-59259-683-5:93. 
 
Roth, B., 2018. National Institute of Mental Health Psychoactive Drug Screening Program 
(NIMH PDSP) Assay Protocol Book Verison III. 
https://pdspdb.unc.edu/pdspWeb/content/PDSP%20Protocols%20II%202013-03-28.pdf 
(accessed 14 August 2018). 
 
Steinberg, G.K., Perez-Pinzon, M.A., Maier, C.M., Sun, G.H., Yoon, E., Kunis, D.M., Bell, TE., 
Powell, M., Kotake, A., Giffard, R., 1994. CGS 19755: correlation of in vitro neuroprotection, 
protection against experimental ischemia and CSF levels in cerebrovascular surgery patients. In: 
Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia; 
Marburg, Germany. 
 
Stringer, J.L, Guyenet, P.G., 1983. Elimination of long-term potentiation in the hippocampus by 
phencyclidine and ketamine. Brain Res. 258, 159-164. https://doi.org/10.1016/0006-
8993(83)91244-1.  
 
Su, T., Hayashi, T., Maurice, T., Buch, S., Ruoho, A.E., 2010. The sigma-1 receptor chaperone 
as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 31.12, 557-566. 
https://doi.org/10.1016/j.tips.2010.08.007. 
 
Sun, S., Sun, S., Wallach, J., Adejare, A., 2014. Syntheses and N-methyl-D-aspartate Receptor 
Antagonist Pharmacology of Fluorinated Arylcycloheptylamines. Med. Chem. 10.8, 843-852. 
https://doi.org/10.2174/1573406410666140428104444. 
 
Thurkauf, A., De Costa, B., Yamaguchi, S., Mattson, M.V., Jacobson, A.E., Rice, K.C., 
Rogawski, M.A., 1990. Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine 
analogs. J. Med. Chem. 33.5, 1452-1458. https://doi.org/10.1021/jm00167a027. 
 
	 17	
UK Chemical Research, 2015. Fluorolintane. https://www.ukchemicalresearch.org/Thread-
Fluorolintane (accessed 1 July 2018). 
 
UNODC, 2018. World Drug Report 2018. Booklet 3. Analysis of drug markets. Opiates, cocaine, 
cannabis, synthetic drugs. United Nations, Vienna, Austria. 
https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_3_DRUG_MARKETS.pdf 
(accessed 14 August 2018).  
 
 
Wallach, J., Brandt, S.D., 2018a. Phencyclidine-based new psychoactive substances. Handb. 
Exp. Pharmacol. https://doi.org/10.1007/164_2018_124.  
 
Wallach, J., Brandt, S.D., 2018b. 1,2-Diarylethylamine- and ketamine-based new psychoactive 
substances. Handb. Exp. Pharmacol.  https://doi.org/10.1007/164_2018_148. 
 
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z.A., Collingridge, G.L., Lodge, D., 
Halberstadt, A.L., Brandt, S.D., Adejare, A., 2016. Pharmacological investigations of the 
dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One. 11.6, 
e0157021. https://doi.org/10.1371/journal.pone.0157021. 
 
Wallach, J., Kavanagh, P.V., McLaughlin, G., Morris, N., Power, J.D., Elliott, S.P., Mercier, 
M.S., Lodge, D., Morris, H., Dempster, N.M., Brandt, S.D., 2015. Preparation and 
characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2, 2 
diphenylethyl isomers. Drug Test. Anal. 7.5, 358-367. https://doi.org/10.1002/dta.1689. 
 
Wallach, J.V., 2014. Structure activity relationship (SAR) studies of arylcycloalkylamines as N-
methyl-D-aspartate receptor antagonists. Diss. University of the Sciences in Philadelphia. 
 
Wink, C.S., Michely, J.A., Jacobsen-Bauer, A., Zapp, J., Maurer, H.H., 2016. Diphenidine, a 
new psychoactive substance: metabolic fate elucidated with rat urine and human liver 
preparations and detectability in urine using GC-MS, LC-MS(n), and LC-HR-MS(n). Drug Test. 
Anal. 8, 1005–1014. https://doi.org/10.1002/dta.1946.  
 
Yenari M A, Bell T E, Kotake A N, Powell M, Steinberg G K (1998) Dose escalation safety and 
tolerance study of the competitive NMDA antagonist selfotel (CGS19755) in neurosurgery 
patients. Clin. Neuropharm 21: 28–34. 
	
	
	 18	
 
 
Fig 1. Structures of known dissociatives (PCP, ketamine and diphenidine), fluorolintane (2-F-
DPPy) and its five possible aryl-F-positional isomers.  
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Fig 2. Competitive binding curves for structural analogs of fluorolintane, DPPy and five 
fluorinated positional isomers using [3H]MK-801 in rat forebrains. Each concentration run in 
duplicate and experiments repeated 3 times.  
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Fig 3. Receptor binding heat map for fluorolintane and five fluorinated positional isomers. 
Numbers provided are Ki values. Green colored box without number means IC50 was >10,000 
nM based on primary experiment. White box means affinity not determined. Full descriptions of 
experimental conditions including full receptor name associated with each abbreviation, 
radioligand use and concentration used are provided in supplemental Table S1.  Additional 
details for non-NMDA receptor binding experiments can be found in the NIMH PDSP assay 
protocol book (Roth. 2018) 
 
 
 
 
Fig 4. Plots showing the time-course of inhibition of NMDA receptor-mediated fEPSPs by 
increasing concentrations of fluorolintane. The top inserts are raw sample traces showing typical 
field excitatory postsynaptic potentials (fEPSPs) extracted from one of the 3 µM experiments. 
The traces (a, b & c) were taken at the times indicated on the plots by the letters in blue. Each 
point in the plots represents the averaged amplitude of 4 successive evoked fEPSPs triggered at 
30 s intervals and recorded in the CA1 region of the hippocampal slices. The data are expressed 
as percentage of the control (mean ± SEM) plotted against time. The bars above the graphs 
indicate the perfusion times for the different concentrations fluorolintane and D-AP5. Each plot 
shows pooled data from the number of experiments indicated in the lower left corner.  
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Fig 5. Fluorolintane blocks the induction of LTP elicited by TBS at CA1 hippocampal synapses.   
A & C show a single representative experiment and B & D show the polled results from 5 and 6 
experiments respectively. The traces are averages of four successive fEPSP responses obtained at 
the times indicated (a & b) for the experiments illustrated in A & C. Graphs A & B show the  
results from 5 interleaved experiments under control conditions and graphs C & D show the 
results from 6 slices incubated in fluorolintane (10 µM). A & B show the induction of LTP by 
TBS delivered (arrow) in the absence of drug after obtaining 30 min of baseline.  In contrast C & 
D show that TBS delivered (arrow) after 30 min of baseline on slices incubated for at least 3 
hours in fluorolintane (Fig 4.). The treatment with fluorolintane blocked the induction of LTP by 
TBS although there was a short post TBS potentiation. Data are presented as mean ± s.e.m. 
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Fig 6. Effect of fluorolintane on startle magnitude and prepulse inhibition of acoustic startle 
(PPI).  A total of 40 rats were used in this experiment (n = 10/group).  PPI values shown are 
averaged across the 3 prepulse intensities (mean ± SEM). *Significant difference compared with 
vehicle control, p<0.01 (Tukey's test). 
	
